ANDE DIGITAL Press Releases - EIN Presswire - Press Release Distribution Service

Published on October 15, 2026 - 00:00 GMT

Henlius’ HANDAYUAN (Adalimumab Biosimilar) Secures DRAP Approval in Pakistan, Marking Its First Overseas Approval

Henlius announces its partner Getz Pharma received DRAP registration for HANDAYUAN, its adalimumab biosimilar, sold as Adaliget in Pakistan. SHANG HAI, SHANGHAI, CHINA, October 15, 2026 /⁨EINPresswire.com⁩/ -- Shanghai Henlius Biotech, Inc. (2696.HK) …

Distribution channels: Business & Economy, Companies ...

Published on September 17, 2026 - 00:00 GMT

Henlius Delivers Strong 2026 Interim Financial Results, Accelerates Global Validation Under Globalisation 2.0 Strategy

Shanghai-based Chinese biopharmaceutical company Henlius has released its interim results for the first half of 2026, reporting robust revenue expansion. SHANG HAI, CHINA, September 17, 2026 /⁨EINPresswire.com⁩/ -- Shanghai-based Chinese biopharmaceutical …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on August 30, 2026 - 00:00 GMT

First Chinese PD-1 Inhibitor Hetronifly® (serplulimab) Recommended by NICE for NHS Lung Cancer Care

UK's NICE recommends China's serplulimab (trade name in Europe: Hetronifly) for routine use within the National Health Service (NHS) in England and Wales SHANGHAI, CHINA, August 30, 2026 /⁨EINPresswire.com⁩/ -- A pioneering immune checkpoint …

Distribution channels: Business & Economy, Companies ...

Published on August 10, 2026 - 00:00 GMT

Final ASTRUM-002 Analysis Shows Survival Benefit with Hetronifly in Advanced nsqNSCLC After Four Years of Follow-Up

SHANGHAI, CHINA, August 10, 2026 /⁨EINPresswire.com⁩/ -- Shanghai Henlius Biotech, Inc. (2696.HK), headquartered in Shanghai and listed on the Hong Kong Stock Exchange, recently announced definitive final survival findings from its proprietary anti-PD-1 …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...